Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADV-TK Gene Therapy for Recurrent High-Grade Glioma
NCT00870181Phase 2Completed
- Sponsor
- Huazhong University of Science and Technology
- Start
- Jan 2008
- Primary completion
- Dec 2011
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of aglatimagene besadenovec in malignant glioma, glioblastoma (GBM), sponsored by Huazhong University of Science and Technology. Started Jan 2008; status: completed.
02
Drugs
aglatimagene besadenovec
03
Conditions
malignant gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT00870181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00870181.